- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
CAMP
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
CAMP4 THERAPEUTICS CORPORATION · Healthcare · Biotechnology
Latest close
3.45 USD
9.2%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -20.4% below the Trend Line and sits at 33.1% of its 52-week range. The latest completed week returned 9.2%, after a -22.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers. The latest news-sentiment score is 59/100. Near-term considerations: volume confirmation is below normal; earnings are due in 11d.
Setup score
19
out of 100
Latest Close
3.45 USD
31 Jul 2026
1W Return
9.2%
latest completed week
4W Return
-22.1%
short-term follow-through
12W Return
-22.6%
quarterly tape
Trend Breadth
53.8%
28 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
9.2%
Latest completed week; four-week move -22.1%.
Indicator stack
30/28
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 41.70%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
59/100
48 relevant articles in the latest sentiment read.
Event risk
11d
Next report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -20.4% below the Trend Line and sits at 33.1% of its 52-week range. The latest completed week returned 9.2%, after a -22.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.2012-week average 0.26
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -22.1% over four weeks, -22.6% over 12 weeks, and 109.1% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year28
Trend breadth53.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.12Latest activity-pressure read.
Pressure change-21.2%Four-week change in activity pressure.
Leadership-20.31Latest relative-leadership reading.
RS change-1336.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks strongly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 79%
Model confidence 76%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength48/100Blend of value, momentum, and quality. Underlying universe rank 53; rank 1 is best.
Value16/100Relative valuation strength. Underlying universe rank 85; rank 1 is best.
Quality67/100Profitability and accounting quality. Underlying universe rank 34; rank 1 is best.
Momentum93/100Medium-term price momentum. Underlying universe rank 8; rank 1 is best.
Growth90/100Revenue and earnings growth. Underlying universe rank 11; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 41.7x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -39.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 76.2% Gross profit retained from each unit of revenue.
- Operating margin
- -1372.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -667.2% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 160.5% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -35.1% Net share repurchases relative to market value.
- Shareholder yield
- -35.1% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 1.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment59/100
Weighted news tone is neutral across 48 relevant articles.
21 positive · 25 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-55.5%Distance below the 52-week high.
13-week volatility7.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher13 of 2612 weeks finished lower.
Best week+28.8%Week of 13 Mar.
Worst week-14.8%Week of 24 Jul.
Latest week+9.2%Week of 31 Jul.
Shape of recent returns
Strong gains6
Modest gains7
Flat weeks1
Modest losses5
Sharp losses7
Recent vol7.5%13-week weekly-return volatility.
Base vol24.6%52-week weekly-return volatility.
Up/down split24/26Count of positive and negative weeks in the 52-week window.
Average skew18.5% / -9.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape22/100
Trend, activity pressure, participation, and risk combine to a 22/100 tape read.
Indicator analysis18/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 4/12.
Activity pressure 0.20; No reversal markers Next-Week ExpectancyNegative 41.70%Next-week expectancy is negative with a 41.70% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 94; Small Cap Core rank 90 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment59/100Weighted news tone is neutral across 48 relevant articles.
Price to earnings forward of CAMP4 Therapeutics Corporation – NASDAQ:CAMP Insiders50/100No recent insider transaction evidence is stored.
Earnings11dNext report is scheduled for 13 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 3.45 USD | 9.2% | 4.33 USD | 4.22 USD | -1.12 | -20.31 | 668.0K | Off |
| 24 Jul 2026 | 3.16 USD | -14.8% | 4.42 USD | 4.23 USD | -0.90 | -26.15 | 962.3K | Off |
| 17 Jul 2026 | 3.71 USD | -14.3% | 4.51 USD | 4.24 USD | -0.81 | -14.31 | 915.6K | Off |
| 10 Jul 2026 | 4.33 USD | -2.3% | 4.60 USD | 4.24 USD | -0.81 | -3.41 | 1.0M | Off |
| 3 Jul 2026 | 4.43 USD | 5.5% | 4.67 USD | 4.24 USD | -0.92 | 1.64 | 634.3K | Off |
| 26 Jun 2026 | 4.20 USD | 1.7% | 4.63 USD | 4.24 USD | -1.10 | -1.68 | 4.1M | Off |
| 19 Jun 2026 | 4.13 USD | -1.4% | 4.62 USD | 4.24 USD | -1.02 | -6.73 | 1.3M | Off |
| 12 Jun 2026 | 4.19 USD | 1.9% | 4.58 USD | 4.24 USD | -0.82 | -1.93 | 420.5K | Off |
| 5 Jun 2026 | 4.11 USD | -6.4% | 4.58 USD | 4.24 USD | -0.73 | -0.65 | 349.6K | Off |
| 29 May 2026 | 4.39 USD | -2.7% | 4.58 USD | 4.24 USD | -0.46 | 2.07 | 321.8K | Off |
| 22 May 2026 | 4.51 USD | 4.6% | 4.57 USD | 4.24 USD | -0.45 | 8.65 | 259.1K | Off |
| 15 May 2026 | 4.31 USD | -3.4% | 4.55 USD | 4.24 USD | -0.49 | 5.92 | 674.1K | Off |
| 8 May 2026 | 4.46 USD | 10.1% | 4.50 USD | 4.24 USD | -0.51 | 9.86 | 243.9K | Off |
| 1 May 2026 | 4.05 USD | -8.8% | 4.48 USD | 4.24 USD | -0.62 | 5.92 | 369.9K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.